{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:43Z","timestamp":1791905803127,"version":"4.3.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytomegalovirus (CMV)-seropositive umbilical cord blood transplantation (CBT) recipients have a high incidence of CMV-associated complications. There are limited data regarding the efficacy of letermovir for preventing clinically significant CMV infection (CS-CMVi), and the impact of letermovir prophylaxis on delayed-onset CMV reactivation after letermovir discontinuation, in CBT recipients. We compared the cumulative incidence of CS-CMVi and CMV detection in 21 CMV-seropositive CBT recipients receiving letermovir prophylaxis with a historical cohort of 40 CBT recipients receiving high-dose valacyclovir prophylaxis. Letermovir was administered on day +1 up to day +98. The cumulative incidence of CS-CMVi was significantly lower by day 98 in the letermovir cohort (19% vs 65%). This difference was lost by 1 year due to a higher incidence of delayed-onset CMV reactivation in the letermovir cohort. No patients developed CMV disease in the letermovir cohort within the first 98 days compared with 2 cases (2.4%) in the high-dose valacyclovir cohort; 2 patients developed CMV enteritis after discontinuing letermovir. Median viral loads were similar in both cohorts. Thus, letermovir is effective at preventing CS-CMVi after CBT, but frequent delayed-onset infections after letermovir discontinuation mandate close monitoring and consideration for extended prophylaxis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004362","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:49:54Z","timestamp":1629215394000},"page":"3113-3119","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients"],"prefix":"10.1182","volume":"5","author":[{"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2902","authenticated-orcid":false,"given":"Danniel","family":"Zamora","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Thur","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-2801","authenticated-orcid":false,"given":"Colleen","family":"Delaney","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5196","authenticated-orcid":false,"given":"Steven A.","family":"Pergam","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy M.","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-7984","authenticated-orcid":false,"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"issue":"6","key":"2021081715342948200_B1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3109\/10428194.2014.963079","article-title":"Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant","volume":"56","author":"Dahi","year":"2015","journal-title":"Leuk Lymphoma."},{"issue":"20","key":"2021081715342948200_B2","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood."},{"issue":"9","key":"2021081715342948200_B3","first-page":"1290","article-title":"High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant","volume":"90","author":"Takami","year":"2005","journal-title":"Haematologica."},{"issue":"2","key":"2021081715342948200_B4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbmt.2009.09.019","article-title":"Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation","volume":"16","author":"Beck","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021081715342948200_B5","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood."},{"issue":"3","key":"2021081715342948200_B6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med."},{"issue":"8900","key":"2021081715342948200_B7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"European Acyclovir for CMV Prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet."},{"issue":"6","key":"2021081715342948200_B8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbmt.2017.03.006","article-title":"Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies","volume":"23","author":"Barker","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2021081715342948200_B9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2021081715342948200_B10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.bbmt.2018.05.008","article-title":"A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients","volume":"24","author":"Hill","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"25","key":"2021081715342948200_B11","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2021081715342948200_B12","doi-asserted-by":"crossref","first-page":"e133960","DOI":"10.1172\/JCI133960","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","volume":"131","author":"Duke","year":"2021","journal-title":"J Clin Invest."},{"issue":"8","key":"2021081715342948200_B13","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood."},{"key":"2021081715342948200_B14","first-page":"blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","author":"Zamora","year":"2021","journal-title":"Blood."},{"issue":"13","key":"2021081715342948200_B15","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood-2007-05-092130","article-title":"Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing","volume":"110","author":"Komanduri","year":"2007","journal-title":"Blood."},{"issue":"4","key":"2021081715342948200_B16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2011.08.018","article-title":"Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation","volume":"18","author":"Jacobson","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2021081715342948200_B17","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2012.06.005","article-title":"Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation","volume":"18","author":"Kanda","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2021081715342948200_B18","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021081715342948200_B19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","article-title":"Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation","volume":"55","author":"Sharma","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2021081715342948200_B20","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V83.7.1971.1971","article-title":"Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis","volume":"83","author":"Li","year":"1994","journal-title":"Blood."},{"issue":"6","key":"2021081715342948200_B21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation."},{"issue":"9","key":"2021081715342948200_B22","first-page":"2365","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT Study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis."},{"key":"2021081715342948200_B23","author":"Extension of letermovir (LET)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/16\/3113\/1817754\/advancesadv2021004362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/16\/3113\/1817754\/advancesadv2021004362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:50:18Z","timestamp":1629215418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/16\/3113\/476542\/Delayed-onset-cytomegalovirus-infection-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,8,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004362","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}